ReviewF1000Research2016
Recent advances in the management of liposarcoma.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 62 citations in OpenAlex.
- Article
- Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice.Medical oncology (Northwood, London, England) · 2025Review
- Surgical management of giant retroperitoneal liposarcoma: a case report and review of the literature.Journal of surgical case reports · 2025Article
- Spinal lesions: a comprehensive radiologic overview.Frontiers in radiology · 2025Review
- HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?World journal of surgical oncology · 2024Article
- Article
- Laparoscopic management of a gastric liposarcoma with malignant transformation from a gastric lipoma: A rare case report.International journal of surgery case reports · 2023Article
- Article
- Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma.Cancer research · 2023Article
- Giant Mediastinal Myxoid Pleomorphic Liposarcoma.Sultan Qaboos University medical journal · 2023Article
- Surgical management of giant recurrent retroperitoneal liposarcoma: a case report and review of the literature.Annals of medicine and surgery (2012) · 2023Article
- Paraplegia due to spinal epidural lipoma without spinal dysraphism in an adolescent patient: a case report.Nagoya journal of medical science · 2022Article
- Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.BMC cancer · 2022Article
- Epithelioid Variant of Pleomorphic Liposarcoma: A Rare Challenging Diagnosis Causing Severe Medial Thigh Pain.Cureus · 2021Article
- Primary pleomorphic liver liposarcoma: A case series and literature review.Annals of hepato-biliary-pancreatic surgery · 2021Article
- Contrast-enhanced ultrasound-guided musculoskeletal biopsies: our experience and technique.Skeletal radiology · 2021Article
- Rare Case of Primary Pulmonary Pleomorphic Liposarcoma Treated With Multimodal Therapy.Ochsner journal · 2021Article
- Primary myxoid liposarcoma of the pelvis: An unusual location.Radiology case reports · 2020Article
- Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma with Myxoid Stroma in a Hereditary Retinoblastoma Survivor.Ocular oncology and pathology · 2020Article
- Clear cell renal carcinoma synchronous with dedifferentiated liposarcoma: a case report and review of the literature.Journal of medical case reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposarcoma is the most common soft tissue sarcoma. With its various subtypes, the natural history of this disease can vary significantly from a locally recurrent tumor to a highly malignant one carrying a poor prognosis. Progress in the understanding of the specific molecular abnormalities in liposarcoma provides greater opportunity for new treatment modalities. Although surgical resection and radiation therapy remain the keystones for the management of primary liposarcoma, the inclusion of novel agents that target known abnormalities in advanced liposarcoma enhances the potential for improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.